Search
Displaying 291–300 of 906 results
-
Opus Genetics Announces Two Key Leadership Appointments
The Foundation in the NewsDr. Ash Jayagopal named Chief Scientific Officer and Mr. Joe Schachle appointed Chief Operating Officer.
-
Atsena Therapeutics Developing X-Linked Retinoschisis Gene Therapy
Eye On the Cure Research NewsThe emerging gene therapy is being designed to more safely reach the fovea
-
Learning to Fall After Vision Loss
Beacon StoriesWhen Justin’s vision loss progressed quickly due to retinitis pigmentosa at 25 years old, he thought skateboarding wouldn’t be possible anymore. Ten years later, with the help of his white cane and audio devices, Justin is now working to enhance accessibility in skateboarding for the blind and visually impaired community.
-
Foundation Fighting Blindness Appoints Richele Donat, SPHR, as Chief Human Resources Officer
Press ReleasesMs. Donat brings over twenty years of successful human resource leadership experience to the Foundation executive team
-
Foundation Hosts Workshop on USH1B Research and Therapy Development
Eye On the Cure Research NewsEmerging dual-vector gene therapies to address current cargo-size limitations were highlighted during the meeting.
-
Covid Revealed What Science Can Do When Funding is Found
The Foundation in the News‘In some ways, the pandemic ought to make us all feel more upbeat about the long-term future of medical research.’
-
RD Fund Appoints Tony Adamis, MD to Board of Directors
Press ReleasesThe RD Fund announces the appointment of Anthony (Tony) Adamis, MD, to its board of directors.
-
Eye On the Cure Research News
The emerging treatment targets a specific mutation (c.2991+1655A>G in Intron 26) of the gene CEP290 which causes Leber congenital amaurosis 10 (LCA 10)
-
RD Fund Launches Opus Genetics to Advance Gene Therapies for Inherited Retinal Diseases
Eye On the Cure Research NewsFirst two programs are for Leber congenital amaurosis: LCA5-lebercillin and LCA13-RDH12
-
Landing Page
Funded Foundation Fighting Blindness Grants and Awards for Fiscal Year 2021 (July 1, 2020–June 30, 2021)
